



OVTL16 (Ovarian carcinoma-associated antigen)

CATALOG NUMBER: MUB1400S

CLONE: OVTL16

SPECIES / ISOTYPE: mouse IgG1

PRODUCT FORM: culture supernatant of monoclonal antibody

BACKGROUND

A central concept in tumor immunology is that malignancies bear tumor associated antigens, which are not or to a much lesser degree found in normal tissues. These antigens can be used as distinctive markers in diagnosis and therapy. As a consequence, monoclonal antibodies to such antigens may represent useful tools for histopathology, immunoscintigraphy and for immunotherapy.

SOURCE

OVTL16 is a mouse monoclonal IgG1 antibody derived by fusion of SP2/0 mouse myeloma cells with spleen cells from a BALB/c mouse immunized with cyst fluid, obtained from a patient with a poorly differentiated human ovarian carcinoma.

PRODUCT

Each vial contains 1 ml of 100 µg/ml purified monoclonal antibody in PBS containing 0.09% sodium azide.

SPECIFICITY

OVTL16 recognizes a conformational epitope on ovarian carcinoma membrane antigen OA3 which is present in ovarian carcinomas and in cyst fluids obtained from these carcinomas, as well as in oviductal carcinomas and some endometrial carcinomas.

OVTL16 is suitable for immunohistochemistry on frozen tissues and for staining with avidin-biotinylated horseradish peroxidase complex (ABC) as detection reagent.

Optimal antibody dilution should be determined by titration.

SPECIES REACTIVITY

Human.

STORAGE

Store at 4°C, or in small aliquots at -20°C.

REFERENCES

1. Boerman, O., Makkink, K., Massuger, L., Thomas, C., Kenemans, P., Hanselaar, T., and Poels, L. (1989). Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids, *Anticancer Res* 9, 551-8.
2. Boerman, O., Massuger, L., Makkink, K., Thomas, C., Kenemans, P., and Poels, L. (1990). Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies. *Anticancer Res* 10, 1289-1295.
3. van Niekerk, C. C., Ramaekers, F. C., Hanselaar, A. G., Aldeweireldt, J., and Poels, L. G. (1993). Changes in expression of differentiation markers between normal ovarian cells and derived tumors, *Am J Pathol* 142, 157-77.
4. Slobbe, R., Poels, L., ten Dam, G., Boerman, O., Nieland, L., Leunissen, J., Ramaekers, F., and van Eys, G. (1994). Analysis of idiotope structure of ovarian cancer antibodies: recognition of the same epitope by two monoclonal antibodies differing mainly in their heavy chain variable sequences, *Clin Exp Immunol* 98, 95-103.
5. van Niekerk, C. C., Vooijs, P., Casparie-van Velsen, I. J., and Poels, L. G. (1997). Differentiation margins of ovarian tumor pathology: first incidences of epithelial ovarian tumors monitored by marker antibodies. *Cancer Detect Prev* 21, 247-257.

© 2009 MUBio Products B.V.

Datasheet version: MUB_1400S_090604

WARNING and CAUTION

This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals.

This product contains sodium azide. To prevent formation of toxic vapors, do not mix with strong acidic solutions. To prevent formation of potentially explosive metallic azides in metal plumbing, always wash into drain with copious quantities of water.

This datasheet is as accurate as reasonably achievable, but MUBio Products BV accepts no liability for any inaccuracies or omissions in this information.